GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Gross Margin %

NeuroMetrix (NeuroMetrix) Gross Margin % : 64.34% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. NeuroMetrix's Gross Profit for the three months ended in Dec. 2023 was $0.85 Mil. NeuroMetrix's Revenue for the three months ended in Dec. 2023 was $1.32 Mil. Therefore, NeuroMetrix's Gross Margin % for the quarter that ended in Dec. 2023 was 64.34%.


The historical rank and industry rank for NeuroMetrix's Gross Margin % or its related term are showing as below:

NURO' s Gross Margin % Range Over the Past 10 Years
Min: 24.22   Med: 49.65   Max: 71.76
Current: 66.88


During the past 13 years, the highest Gross Margin % of NeuroMetrix was 71.76%. The lowest was 24.22%. And the median was 49.65%.

NURO's Gross Margin % is ranked better than
73.24% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.575 vs NURO: 66.88

NeuroMetrix had a gross margin of 64.34% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for NeuroMetrix was 15.60% per year.


NeuroMetrix Gross Margin % Historical Data

The historical data trend for NeuroMetrix's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Gross Margin % Chart

NeuroMetrix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.22 71.16 71.76 69.65 66.89

NeuroMetrix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.59 69.45 67.57 65.00 64.34

Competitive Comparison of NeuroMetrix's Gross Margin %

For the Medical Devices subindustry, NeuroMetrix's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroMetrix's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Gross Margin % distribution charts can be found below:

* The bar in red indicates where NeuroMetrix's Gross Margin % falls into.



NeuroMetrix Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

NeuroMetrix's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=3.9 / 5.901
=(Revenue - Cost of Goods Sold) / Revenue
=(5.901 - 1.954) / 5.901
=66.89 %

NeuroMetrix's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.8 / 1.318
=(Revenue - Cost of Goods Sold) / Revenue
=(1.318 - 0.47) / 1.318
=64.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


NeuroMetrix  (NAS:NURO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

NeuroMetrix had a gross margin of 64.34% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


NeuroMetrix Gross Margin % Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroMetrix (NeuroMetrix) Business Description

Traded in Other Exchanges
N/A
Address
4B Gill Street, Woburn, MA, USA, 01801
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Executives
Bradley M Fluegel director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins officer: Chief Financial Officer
Topline Capital Management, Llc other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp 10 percent owner 544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani director, officer: Chairman, President and CEO C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin officer: Senior VP, Consumer C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van director C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran officer: S. VP and GM, International C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz director CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc officer: Senior Vice President & GM
Walter Christensen officer: Sr. VP, Global Sales C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor director 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C) 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017